Stocktoria
Immuneering Corp IMRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-07-30
Immuneering Corp statistics & valuation
Market cap$308.0M
P / B1.4×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | — | — | — | 50.1% | 44.6% |
| Operating margin | — | — | — | -16325.8% | -1629.2% |
| Net margin | — | — | — | -15937.3% | -1612.3% |
| FCF margin | — | — | — | -14148.4% | -1486.2% |
| Return on assets | -24.2% | -115.8% | -52.1% | -41.3% | -20.1% |
| Return on equity | -25.6% | -147.5% | -59.0% | -46.0% | -21.5% |
| Current ratio | 17.50 | 5.28 | 11.35 | 13.50 | 27.04 |
| Revenue growth | — | — | -100.0% | -84.8% | -10.0% |
Source: SEC EDGAR filings · CIK 0001790340 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.